NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 34,400 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 34,400 shares of the stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $32.78, for a total transaction of $1,127,632.00. Following the sale, the chief accounting officer owned 24,353 shares of the company’s stock, valued at $798,291.34. This trade represents a 58.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Friday, January 23rd, Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.75, for a total transaction of $1,288,305.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.25, for a total transaction of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.30, for a total value of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Stock Performance

NewAmsterdam Pharma stock opened at $32.63 on Wednesday. The business’s fifty day moving average is $35.46 and its two-hundred day moving average is $31.24. The firm has a market cap of $3.70 billion, a P/E ratio of -15.92 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $4.54 million. NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. On average, equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Arizona State Retirement System boosted its holdings in NewAmsterdam Pharma by 3.8% during the third quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock worth $377,000 after buying an additional 483 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of NewAmsterdam Pharma by 2.4% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 22,549 shares of the company’s stock valued at $408,000 after acquiring an additional 521 shares during the period. The Manufacturers Life Insurance Company boosted its stake in NewAmsterdam Pharma by 5.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after acquiring an additional 544 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in NewAmsterdam Pharma by 18.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock valued at $79,000 after purchasing an additional 662 shares during the period. Finally, Farther Finance Advisors LLC increased its stake in NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after purchasing an additional 708 shares in the last quarter. Institutional investors own 89.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. The Goldman Sachs Group increased their price target on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research note on Tuesday, December 2nd. Needham & Company LLC increased their price objective on NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. HC Wainwright started coverage on NewAmsterdam Pharma in a research report on Monday, October 20th. They set a “buy” rating and a $52.00 target price for the company. Stifel Nicolaus raised their price target on NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Finally, Royal Bank Of Canada boosted their price objective on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $47.00.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.